Support program has roots in Basel
The online program Selfapy supports people suffering from mental health conditions during the coronavirus lockdown. BaselArea.swiss has provided startup help by way of its DayOne initiative.
The regional business promotion organization BaselArea.swiss is implementing numerous measures to support medical innovations by way of its DayOne initiative. In this context, the DayOne Experts event was held back in February, which placed the focus squarely on the issue of mental health. The participants included Professor Gunther Meinlschmidt, Research Director at the Department of Psychosomatic Medicine at the University Hospital Basel, in addition to the Berlin-based startup Selfapy. Following the event in Basel, Meinlschmidt and Selfapy have developed an online course for people suffering from mental health disorders during the COVID-19 lockdown period.
The free Selfapy program begins with an informative talk over the telephone or via email. During the online course, participants receive access to interactive exercises, videos and informative texts. A psychologist supports the participants and answers any questions they might have. In addition, the participants will be assessed personally and receive feedback on their progress.
“We followed the approach of developing a relatively broad service to offer those affected”, comments Meinlschmidt in an interview published on the website of the International Psychoanalytic University Berlin. “It consists of 12 modules into which we poured general knowledge relating to coping mechanisms and resources in the context of catastrophes and mental illnesses, all connected with specific strategies tailored to the current COVID-19 situation”, he adds. The service can be used by anyone aged 18 or over and is aimed at “people who are feeling the strain and want to do something to improve their mental health and feel less stressed during the ongoing pandemic situation.”
Share this article
You might also be interested in
The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..Read More
Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.Read More
Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.Read More
The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.Read More
Basel/Liestal/Delémont – Because of the coronavirus crisis.the three sponsor cantons of BaselArea.swiss have adopted emergency aid measures in addition to those agreed by the Swiss government at national level. The cantons of Basel-Stadt, Basel-Landschaft and Jura will be supporting companies and other individuals affected to a substantial extent. The aim here is to mitigate the consequences of the coronavirus pandemic within the economic region of Basel Area.Read More
The Basel-based pharmaceutical company Roivant Sciences wants to develop a special antibody for coronavirus patients. This is intended to help treat and prevent acute respiratory distress syndrome.Read More
The US regulatory authority has authorized a test developed by the Basel-based pharmaceutical company Roche to detect the SARS-CoV 2 virus. Due to Roche’s work, numerous additional tests can be carried out in the USA, and for this reason Roche received the express thanks of President Trump.Read More